Mahdinloo Somayeh, Kiaie Seyed Hossein, Amiri Ala, Hemmati Salar, Valizadeh Hadi, Zakeri-Milani Parvin
Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz 5166616471, Iran.
Nano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran.
Acta Pharm Sin B. 2020 Jul;10(7):1279-1293. doi: 10.1016/j.apsb.2020.03.007. Epub 2020 Apr 21.
Liver fibrosis results from chronic damages together with an accumulation of extracellular matrix, and no specific medical therapy is approved for that until now. Due to liver metabolic capacity for drugs, the fragility of drugs, and the presence of insurmountable physiological obstacles in the way of targeting, the development of efficient drug delivery systems for anti-fibrotics seems vital. We have explored articles with a different perspective on liver fibrosis over the two decades, then collected and summarized the information by providing corresponding and cases. We have discussed the mechanism of hepatic fibrogenesis with different ways of fibrosis induction in animals. Furthermore, the critical chemical and herbal anti-fibrotics, biological molecules such as micro-RNAs, siRNAs, and growth factors, which can affect cell division and differentiation, are mentioned. Likewise, drug and gene delivery and therapeutic systems on and models are summarized in the data tables. This review article enlightens recent advances in emerging drugs and nanocarriers and represents perspectives on targeting strategies employed in liver fibrosis treatment.
肝纤维化是由慢性损伤以及细胞外基质的积累引起的，到目前为止尚未批准针对其的特异性药物治疗。由于肝脏对药物的代谢能力、药物的脆弱性以及靶向过程中存在不可逾越的生理障碍，开发用于抗纤维化的高效药物递送系统显得至关重要。在过去二十年中，我们从不同角度探讨了有关肝纤维化的文章，然后通过提供相应的案例收集并总结了相关信息。我们讨论了动物中不同纤维化诱导方式下的肝纤维化发生机制。此外，还提到了关键的化学和草药抗纤维化药物、可影响细胞分裂和分化的生物分子，如微小RNA、小干扰RNA和生长因子。同样，在数据表中总结了基于细胞和动物模型的药物和基因递送及治疗系统。这篇综述文章阐述了新兴药物和纳米载体的最新进展，并展示了肝纤维化治疗中所采用靶向策略的观点。
